|
시장보고서
상품코드
2091545
급성 폐손상 시장 규모, 점유율, 성장 분석 : 치료 분류별, 치료법별, 중증도 분류별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Acute Lung Injury Market Size, Share, and Growth Analysis, By Therapeutic Class (Corticosteroids, Vasodilators), By Treatment Modality, By Severity Classification, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 급성 폐손상(ALI) 시장 규모는 2024년에 6억 3,270만 달러로 평가되었으며, 2025년 6억 6,054만 달러에서 2033년까지 9억 3,219만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 4.4%로 성장할 것으로 전망됩니다.
세계 급성 폐손상(ALI) 시장은 신속한 승인 절차를 촉진하는 규제적 노력에 힘입어, 흡입형 계면활성제 및 펩타이드와 같은 치료법 개발이 가속화되면서 현저한 성장을 이루고 있습니다. 이러한 급속한 발전으로 인해 자본 리스크가 완화되고, 벤처 캐피털 유치가 이루어지며, 다양한 지역에서 대규모 임상시험의 실시가 촉진되고 있습니다. 진단 기술의 혁신, 특히 AI를 활용한 솔루션은 질환의 탐지 정확도와 속도를 향상시킴으로써 시장 상황을 일신하고 있습니다. 이러한 발전으로 인해 치료가 신속해지고, 집중 치료 기간이 단축되며, 환자의 예후가 개선됨에 따라, 의료 현장에서 AI 도구에 대한 수요가 증가하고 있습니다. 또한, 전자 차트와의 원활한 연동을 통해 환자를 지속적으로 모니터링할 수 있게 되어 업무 흐름이 효율화되고, 침습적 시술의 필요성이 줄어듭니다. 이를 통해 보다 효율적이고 환자 중심의 진료 경험이 실현될 뿐만 아니라, 시장 진출 기회도 확대되고 있습니다.
세계 급성 폐손상 시장의 성장요인
급성 호흡곤란 증후군 및 폐렴을 포함한 중증 호흡기질환의 발생률 증가는 급성 폐손상과 관련된 치료법에 대한 수요를 크게 끌어올리고 있습니다. 고령화의 진행과 환경 오염 물질에 대한 노출 증가로 인해 집중 치료가 필요한 환자 수가 늘어나고 있는 만큼, 의료진은 환자 한 명 한 명에게 맞춘 치료 전략을 시행하고, 종합적인 치료 경로에 자원을 배분할 수밖에 없는 상황에 놓여 있습니다. 이러한 증가하는 임상적 수요에 따라, 병원들은 폐 손상을 효과적으로 관리하기 위한 전문적인 진단 도구, 약물 요법 및 보조 기기의 도입을 추진하고 있습니다. 그 결과, 이러한 추세는 전 세계 의료 시스템 및 연구 기관 시장의 전반적인 확대에 기여하고 있습니다.
세계 급성 폐손상 시장의 제약요인
세계 급성 폐손상 시장은 첨단 치료법에 따른 높은 비용으로 인해 큰 제약에 직면해 있습니다. 많은 의료 시설, 특히 개발도상국 지역에서는 고가의 장비와 전문적인 소모품, 그리고 효과적인 치료를 위해 필요한 광범위한 교육으로 인해 발생하는 재정적 부담으로 어려움을 겪고 있습니다. 그 결과, 예산이 제한된 병원에서는 이러한 치료법에 대한 투자보다 필수 의료 서비스를 우선시하는 경우가 많아, 명백한 임상적 이점이 있음에도 불구하고 도입률이 낮은 실정입니다. 이러한 상황은 시장의 성장을 저해할 뿐만 아니라, 소규모 진료소가 첨단 기술을 도입하는 것을 주저하게 만들어 의료 격차를 초래하고 있습니다. 그 결과, 제조사들은 효능을 확보하면서도 비용 대비 효과가 더 높은 솔루션을 고안해야 하는 압박을 받고 있으며, 이는 시장 침투를 저해할 가능성이 있습니다.
세계 급성 폐손상 시장의 동향
세계 급성 폐손상 시장에서는 정밀한 면역 조절을 향한 뚜렷한 추세가 나타나고 있으며, 치료 프로토콜이 근본적으로 변화하고 있습니다. 분자 프로파일링 기술을 활용함으로써, 의료진은 표적형 사이토카인 억제제의 혜택을 받을 수 있는 특정 환자 하위 집단을 파악할 수 있게 되었으며, 이를 통해 치료 결과의 편차를 최소화할 수 있게 되었습니다. 이러한 변화는 생명공학 기업과 학술 기관 간의 협력을 촉진하고 있으며, 초기 단계의 임상시험을 가속화하고 혁신적인 플랫폼 기술에 대한 투자를 유치하고 있습니다. 안전성 향상과 회복 기간 단축으로 인해 3차 의료 현장에서 이러한 치료법의 도입이 확대되고 있으며, 정밀 면역 조절은 현대 및 미래의 치료 접근 방식에서 매우 중요한 요소로 자리매김하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 급성 폐손상 시장 규모 : 치료 분류별
세계의 급성 폐손상 시장 규모 : 치료 모달리티별
세계의 급성 폐손상 시장 규모 : 중증도 분류별
세계의 급성 폐손상 시장 규모 : 최종사용자별
세계의 급성 폐손상 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.07.23Global Acute Lung Injury Market size was valued at USD 632.7 Million in 2024 and is poised to grow from USD 660.54 Million in 2025 to USD 932.19 Million by 2033, growing at a CAGR of 4.4% during the forecast period (2026-2033).
The global Acute Lung Injury (ALI) market is experiencing significant expansion driven by regulatory initiatives that promote expedited pathways, enabling faster development of therapies such as inhaled surfactants and peptides. This rapid progression reduces capital risks, attracting venture capital and facilitating larger clinical trials across diverse regions. Innovations in diagnostic technologies, particularly AI-driven solutions, are reshaping the landscape by improving the accuracy and speed of disease detection. These advancements lead to quicker treatment, reduced intensive care durations, and enhanced patient outcomes, subsequently increasing demand for AI tools in healthcare settings. Furthermore, seamless integration with electronic health records fosters continuous patient monitoring, streamlining workflows and lessening the need for invasive procedures, resulting in a more efficient and patient-centered care experience while expanding market accessibility.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Acute Lung Injury market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Acute Lung Injury Market Segments Analysis
Global acute lung injury market is segmented by therapeutic class, treatment modality, severity classification, end user and region. Based on therapeutic class, the market is segmented into Corticosteroids, Vasodilators, Surfactant Therapy, Fluid Management Agents, Novel Biologics and Others. Based on treatment modality, the market is segmented into Pharmacological Therapeutics, Mechanical Ventilation Support, Extracorporeal Membrane Oxygenation and Others. Based on severity classification, the market is segmented into Mild Acute Lung Injury, Moderate Acute Lung Injury and Severe Acute Lung Injury. Based on end user, the market is segmented into Hospitals, Intensive Care Units, Specialty Respiratory Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Acute Lung Injury Market
The increasing incidence of severe respiratory conditions, including acute respiratory distress syndrome and pneumonia, significantly boosts the demand for solutions related to acute lung injury. As aging populations and heightened exposure to environmental pollutants lead to a greater number of patients requiring intensive care, healthcare providers are compelled to implement tailored therapeutic strategies and allocate resources towards comprehensive care pathways. This growing clinical demand drives hospitals to adopt specialized diagnostic tools, pharmacological treatments, and supportive devices aimed at effectively managing lung injuries. Consequently, this trend contributes to the overall expansion of the market within healthcare systems and research institutions globally.
Restraints in the Global Acute Lung Injury Market
The Global Acute Lung Injury market faces significant restraints due to the high costs associated with advanced therapies. Many healthcare facilities, especially in less developed areas, struggle with the financial burden imposed by expensive equipment, specialized supplies, and the need for extensive training to deliver effective treatment. As a result, hospitals with limited budgets often prioritize essential services over investing in these therapies, leading to lower adoption rates despite the evident clinical advantages. This situation not only hinders market growth but also discourages smaller clinics from acquiring advanced technologies, creating disparities in care. Consequently, manufacturers are pressured to devise more cost-effective solutions while ensuring efficacy, which may impede their market reach.
Market Trends of the Global Acute Lung Injury Market
The Global Acute Lung Injury market is witnessing a significant trend towards precision immunomodulation, fundamentally transforming treatment protocols. By employing molecular profiling techniques, healthcare providers are able to pinpoint specific patient sub-populations that benefit from targeted cytokine inhibitors, thereby minimizing variability in treatment outcomes. This shift is catalyzing partnerships between biotech companies and academic institutions, which are expediting early-phase clinical trials and attracting investments in innovative platform technologies. Enhanced safety profiles and expedited recovery periods are driving the adoption of these therapies in tertiary care settings, establishing precision immunomodulation as a pivotal element of contemporary and future treatment approaches.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Acute Lung Injury Market Size by Therapeutic Class & CAGR (2026-2033)
- Market Overview
- Corticosteroids
- Methylprednisolone
- Dexamethasone
- Vasodilators
- Surfactant Therapy
- Fluid Management Agents
- Novel Biologics
- Others
Global Acute Lung Injury Market Size by Treatment Modality & CAGR (2026-2033)
- Market Overview
- Pharmacological Therapeutics
- Mechanical Ventilation Support
- Extracorporeal Membrane Oxygenation
- Others
Global Acute Lung Injury Market Size by Severity Classification & CAGR (2026-2033)
- Market Overview
- Mild Acute Lung Injury
- Moderate Acute Lung Injury
- Severe Acute Lung Injury
Global Acute Lung Injury Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Intensive Care Units
- Specialty Respiratory Clinics
- Others
Global Acute Lung Injury Market Size & CAGR (2026-2033)
- North America (Therapeutic Class, Treatment Modality, Severity Classification, End User)
- US
- Canada
- Europe (Therapeutic Class, Treatment Modality, Severity Classification, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Therapeutic Class, Treatment Modality, Severity Classification, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Therapeutic Class, Treatment Modality, Severity Classification, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Therapeutic Class, Treatment Modality, Severity Classification, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Windtree Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Edesa Biotech, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Stemedica Cell Technologies, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Histocell
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- APEPTICO Forschung und Entwicklung GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ReAlta Life Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Apeiron Biologics AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Qx Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioAegis Therapeutics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vasomune Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Implicit Bioscience
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Angion Biomedica Corp.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AnGes, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
